Showing 5221-5230 of 9772 results for "".
- Hydrafacial Improves Acne Skin Concerns: Studyhttps://practicaldermatology.com/news/hydrafacial-improves-acne-skin-concerns-study/2461501/Hydrafacial improves acne skin concerns, according to a new study published in the Journal of Clinical and Aesthetic Dermatology (JCAD). Fully 100 percent of study participants reported clearer, less inflamed skin after a series of treatments with Hydrafacial’s pate
- Regenerative Medicine in Action: Scars Faded Using Transplanted Hair Follicleshttps://practicaldermatology.com/news/regenerative-medicine-in-action-scars-faded-using-transplanted-hair-follicles/2461486/Skin scars began to behave more like uninjured skin after they were treated with hair follicle transplants in a small new study. The scarred skin harboured new cells and blood vessels, remodelled collagen to restore healthy patterns, and even expressed genes found in healthy unscarred s
- Coming Soon? The first FDA-approved Topical Prescription Product for Molluscumhttps://practicaldermatology.com/news/coming-soon-the-first-fda-approved-topical-prescription-product-for-molluscum/2461485/Ligand Pharmaceuticals Inc.’s partner Novan submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum. Assuming the filing is accepted b
- Acelyrin Inc. to Accelerate Development of Izokibep in HShttps://practicaldermatology.com/news/acelyrin-incs-to-accelerate-development-of-izokibep-in-hs/2461484/Acelyrin Inc’s Izokibep achieved higher orders of Hidradenitis Suppurativa Clinical Responses (HiSCR) in open label Part A of a Phase 2b/3 trial. Izokibep has been administered to over 300 patients, some for up to three years. It is a small therapeutic protein inhibitor
- UCSF Apologizes for Dermatology Experiments in Prisoners in 1960shttps://practicaldermatology.com/news/ucsf-apologizes-for-dermatology-experiments-in-prisoners-in-1960s/2461477/The University of California, San Francisco apologized for conducting unethical dermatology experiments on at least 2,600 incarcerated men in the 1960s and 1970s. Experiments included putting pesticides and herbicides on the men’s skin and injecting it into the
- Endo Removes Qwo from Market Due to Concerns About Injection Site Bruising, Skin Discolorationhttps://practicaldermatology.com/news/endo-removes-qwo-from-market-due-to-concerns-about-injection-site-bruising-skin-discoloration/2461467/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- American Hair Research Society to Host Hybrid Alopecia Areata Summit 12/10-11https://practicaldermatology.com/news/american-hair-research-society-to-host-hybrid-alopecia-areata-summit-1210-11/2461459/The Alopecia Areata Summit “New Pathways, New Treatments” organized by the American Hair Research Society will be held December 10-11 at the New York Academy of Medicine, 1216 5th Ave., New York, NY. The meeting is being co-Chaired by Angela M. Christiano, PhD, Columbia Univ
- Study: Isolated Nail PsO Not Linked to Metabolic Syndrome Riskhttps://practicaldermatology.com/news/study-isolated-nail-psoriasis-not-linked-to-metabolic-syndrome-risk/2461456/Isolated nail psoriasis does not increase risk for metabolic syndrome, according to a letter to the editor in the Journal of the European Academy of Dermatology & Venereology. The analysis include
- MyHealthTeam and Arcutis Biotherapeutics Launch Social Network for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/myhealthteam-and-arcutis-biotherapeutics-launch-social-network-for-people-living-with-seborrheic-dermatitis/2461454/
- James R. Headley Joins ELEVAI LABS as Strategic Advisorhttps://practicaldermatology.com/news/james-r-headley-joins-elevai-labs-as-strategic-advisor-a-strategic-advisor/2461450/Cosmetic industry veteran James R. Headley is joining